Skip to main content
Premium Trial:

Request an Annual Quote

Tailor Bio Receives £650K UK Biomedical Grant to Develop Predictive Diagnostic for Ovarian Cancer

NEW YORK – UK-based startup Tailor Bio has received £650,000 ($771,767) through the Innovate UK Biomedical Catalyst Award in support of its ambitions to develop a pan-cancer precision medicine platform.

Tailor will use the funds to develop its first diagnostic to identify which high-grade serous ovarian cancer patients will not respond to doxorubicin chemotherapy. In the UK, 7,000 women are diagnosed with ovarian cancer each year, and only half will respond to doxorubicin, a commonly prescribed treatment.

The startup will collaborate with Illumina and the University of Cambridge on developing the diagnostic. The partners will also assess the compatibility of Tailor's platform with the Illumina TruSight Oncology Comprehensive assay, which now has CE-IVD marking in Europe.

"In addition to addressing an unmet need in ovarian cancer, Tailor's doxorubicin test is a pivotal step for us to validate our precision medicine platform," Tailor CEO Jason Yip said in a statement. "Stratifying patients away from ineffective treatment is beneficial, but the ultimate aim of Tailor Bio is to develop better therapeutic treatments for cancers with chromosomal instability."

The science underlying Tailor's commercial ambitions originated at the Cancer Research UK Cambridge Institute and the Spanish National Cancer Research Centre. In June, research led by two Tailor Bio executives and published in Nature explored copy number signatures that coincide with chromosomal instability as potential prognostic and predictive biomarkers for cancer. Based on that research, the authors established Tailor Bio to further validate these biomarkers and bring them to the clinic.

Tailor Bio launched in 2020 out of the Illumina Accelerator program, which provides seed funding, access to Illumina platforms, business and scientific expertise, and access to lab space.

The Scan

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.

Meta AI Computer Model Rapidly Predicts Hundreds of Millions of Metagenomic Proteins

Meta AI researchers describe in Science a new large language model that can predict the structures of millions of metagenomic proteins.

Hutch Team Develops Platform for Assessing Impact of SARS-CoV-2 Spike Mutations

The approach described in Cell relies on lentiviral pseudotyping for mutational scanning, which the researchers applied to the SARS-CoV-2 spike protein.

Potential New Therapeutic Target for Rheumatoid Arthritis Discovered

Researchers report in the American Journal of Human Genetics that SNPs implicated in rheumatoid arthritis often regulate the expression of the inflammation-related SPRED2 gene.